Alvotech (ALVO)
NASDAQ: ALVO · Real-Time Price · USD
8.86
-0.12 (-1.34%)
Oct 16, 2025, 10:22 AM EDT - Market open
Alvotech Employees
Alvotech had 1,012 employees as of December 31, 2024. The number of employees increased by 13 or 1.30% compared to the previous year.
Employees
1,012
Change (1Y)
13
Growth (1Y)
1.30%
Revenue / Employee
$555,808
Profits / Employee
$62,607
Market Cap
2.77B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1,012 | 13 | 1.30% |
| Dec 31, 2023 | 999 | 82 | 8.94% |
| Dec 31, 2022 | 917 | 133 | 16.96% |
| Dec 31, 2021 | 784 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ALVO News
- 1 day ago - Alvotech: Promising Vertically Integrated Biosimilar Platform - Seeking Alpha
- 9 days ago - My Top 5 Biotech Stocks Big Pharma Could Buy Next - Seeking Alpha
- 10 days ago - European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency - GlobeNewsWire
- 24 days ago - European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech's Proposed Biosimilar to Prolia® and Xgeva® - GlobeNewsWire
- 24 days ago - European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech's Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner - GlobeNewsWire
- 27 days ago - Alvotech Announces Marketing Approval in Japan of Three New Biosimilars - GlobeNewsWire
- 5 weeks ago - Alvotech (ALVO) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 6 weeks ago - Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York - GlobeNewsWire